Headache
-
The following article from Headache: The Journal of Head and Face Pain, "Prevalence and Burden of Headache Disorders: A Comparative Regional Study in China," by Ning Luo PhD, Yannan Fang PhD, Feng Tan MD, Qian Zhang MD, Daliang Zou MD, Xiutang Cao PhD, Xuehua Xu MD, Hua Bai MD, Jiangang Ou MD, Haike Wu MD, Zilong Chen MD, Yane Zhou MD, Saiying Wan MD, Yan Hong MD, Jingliang Wang MD, Minghui Ding MD, Aiwu Zhang PhD, Daoyuan Zhu MD, Jun Dun PhD, published online on November 10, 2010 (DOI: 10.1111/j.1526-4610.2010.01795.x) on Wiley Online Library (http://www.onlinelibrary.wiley.com), has been retracted per agreement between the authors, the journal's Editor-in-Chief, John F. Rothrock, and Wiley Periodicals, Inc. This retraction has been made due to the article having been erroneously submitted to the journal prematurely in non-final form and without all authors having agreed to publication.
-
Observational Study
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
We sought to assess the safety and tolerability of 3 calcitonin gene-related peptide (CGRP) monoclonal antibodies in patients with chronic migraine who have failed multiple classes of migraine preventive therapies. ⋯ In patients with chronic migraine, the 3 CGRP monoclonal antibodies were well tolerated, and reduced the number of severe headache days.
-
Randomized Controlled Trial
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with and without comorbid anxiety and/or depression. ⋯ A medical history of anxiety and/or depression does not seem to interfere with response to galcanezumab among patients with episodic migraine, and both doses of galcanezumab appear efficacious for these individuals regardless of this psychiatric history. Among patients with chronic migraine and comorbid anxiety and/or depression, the 240-mg dose, but not the 120-mg dose, significantly decreased overall MHD, but neither dose resulted in significantly greater functional improvement. Patients with migraine and comorbid anxiety and/or depression often require additional interventions, and this may be more important in chronic migraine.
-
Randomized Controlled Trial Multicenter Study
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
To evaluate whether quarterly or monthly administration of fremanezumab for migraine prevention exhibits a pattern of decreased efficacy toward the end of the dosing interval (wearing-off effect). ⋯ This analysis of data from a long-term, phase 3 study showed that patients receiving quarterly fremanezumab or monthly fremanezumab did not experience a wearing-off effect toward the end of the dosing interval.
-
To summarize available literature regarding headache as a manifestation of coronaviruses and to describe potential underlying mechanisms. ⋯ According to the Centers for Disease Control, common symptoms of human coronavirus include fever, cough, runny nose, sore throat, and headache. In the case of SARS-CoV-2, there are limited reports about headaches, one of the most common clinical manifestations. There are currently no studies that focus specifically on headache among patients with SARS-CoV-2 infection.